Emerging Therapies in the Treatment of Advanced Melanoma
- 5 August 2021
- journal article
- review article
- Published by Elsevier in Clinics in Plastic Surgery
- Vol. 48 (4) , 713-733
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in MelanomaNew England Journal of Medicine, 2014
- Phase 2 Study of Intralesional PV-10 in Refractory Metastatic MelanomaAnnals of Surgical Oncology, 2014
- First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid TumorsClinical Cancer Research, 2012
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialThe Lancet, 2012
- Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth InhibitionCancer Research, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced MelanomaNew England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010
- Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic CellsJournal of Clinical Oncology, 2003